Provided by Tiger Trade Technology Pte. Ltd.

Cadrenal Therapeutics, Inc.

1.60
-0.0101-0.63%
Volume:14.88K
Turnover:24.04K
Market Cap:5.71M
PE:-0.33
High:1.69
Open:1.69
Low:1.56
Close:1.61
52wk High:14.64
52wk Low:1.54
Shares:3.57M
Float Shares:3.14M
Volume Ratio:0.32
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8667
EPS(LYR):-6.6394
ROE:-275.16%
ROA:-125.93%
PB:1.39
PE(LYR):-0.24

Loading ...

Company Profile

Company Name:
Cadrenal Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2022
Employees:
- -
Office Location:
822 A1A North,Suite 306,Ponte Vedra,Florida,United States
Zip Code:
32082
Fax:
- -
Introduction:
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Directors

Name
Position
Quang X. Pham
Chairman of the Board,Chief Executive Officer and Director
Glynn Wilson
Independent Director
John R. Murphy
Independent Director
Lee Golden
Independent Director

Shareholders

Name
Position
Quang X. Pham
Chairman of the Board,Chief Executive Officer and Director
Jeffrey Cole
Chief Operating Officer
John P. Sharp
Interim Chief Financial Officer